PI3K/Akt/mTOR inhibitors in breast cancer
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2015-12-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/888 |
id |
doaj-185963dc0d2c472dbcf84dd8e2be2cc8 |
---|---|
record_format |
Article |
spelling |
doaj-185963dc0d2c472dbcf84dd8e2be2cc82020-11-25T00:28:36ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412015-12-0112434235410.7497/j.issn.2095-3941.2015.00892015000089PI3K/Akt/mTOR inhibitors in breast cancerJoycelyn JX Lee0Kiley Loh1Yoon-Sim Yap2Department of Medical Oncology, National Cancer Center Singapore, Singapore 169610, SingaporeDepartment of Medical Oncology, National Cancer Center Singapore, Singapore 169610, SingaporeDepartment of Medical Oncology, National Cancer Center Singapore, Singapore 169610, SingaporeActivation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors and breast cancer. Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this review, we summarise the efficacy and toxicity findings from the randomised clinical trials, with simplified guidelines on the management of potential adverse effects. Education of healthcare professionals and patients is critical for safety and compliance. While there is some clinical evidence of activity of mTOR inhibition in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than in the overall population. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the PI3K/Akt/mTOR (PAM) pathway.http://www.cancerbiomed.org/index.php/cocr/article/view/888Breast cancerphosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)everolimus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joycelyn JX Lee Kiley Loh Yoon-Sim Yap |
spellingShingle |
Joycelyn JX Lee Kiley Loh Yoon-Sim Yap PI3K/Akt/mTOR inhibitors in breast cancer Cancer Biology & Medicine Breast cancer phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) everolimus |
author_facet |
Joycelyn JX Lee Kiley Loh Yoon-Sim Yap |
author_sort |
Joycelyn JX Lee |
title |
PI3K/Akt/mTOR inhibitors in breast cancer |
title_short |
PI3K/Akt/mTOR inhibitors in breast cancer |
title_full |
PI3K/Akt/mTOR inhibitors in breast cancer |
title_fullStr |
PI3K/Akt/mTOR inhibitors in breast cancer |
title_full_unstemmed |
PI3K/Akt/mTOR inhibitors in breast cancer |
title_sort |
pi3k/akt/mtor inhibitors in breast cancer |
publisher |
China Anti-Cancer Association |
series |
Cancer Biology & Medicine |
issn |
2095-3941 2095-3941 |
publishDate |
2015-12-01 |
description |
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors and breast cancer. Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this review, we summarise the efficacy and toxicity findings from the randomised clinical trials, with simplified guidelines on the management of potential adverse effects. Education of healthcare professionals and patients is critical for safety and compliance. While there is some clinical evidence of activity of mTOR inhibition in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than in the overall population. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the PI3K/Akt/mTOR (PAM) pathway. |
topic |
Breast cancer phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) everolimus |
url |
http://www.cancerbiomed.org/index.php/cocr/article/view/888 |
work_keys_str_mv |
AT joycelynjxlee pi3kaktmtorinhibitorsinbreastcancer AT kileyloh pi3kaktmtorinhibitorsinbreastcancer AT yoonsimyap pi3kaktmtorinhibitorsinbreastcancer |
_version_ |
1725335343316598784 |